Results 71 to 80 of about 143,594 (301)

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul, Robert J. Mentz, Rebecca Young, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Piotr Ponikowski, Adriaan Voors, Stefano Corda, Ciaran McMullan, Christopher M. O'Connor, Kevin J. Anstrom, Paul W. Armstrong, for the VICTORIA Study Group   +13 more
wiley   +1 more source

Predicting of Long-term Maintenance of Sinus Rhythm after Cardioversion in Patients with Nonvalvular Persistent Atrial Fibrillation

Львівський клінічний вісник, 2014
Introduction. The choice of the optimal strategy for conducting the patients with persistent atrial fibrillation (AF) and the expediency of prolonged antiarrhythmic treatment after cardioversion is highly dependent on the probability of relapse of ...
Zharinov O., Levchuk N., Ikorkin M., Sychov O.   +3 more
doaj   +1 more source

Chronic beta-adrenoceptor blockade and human atrial cell electrophysiology: evidence of pharmacological remodelling [PDF]

, 2003
<b>Objective:</b> Chronic beta-adrenoceptor antagonist (β-blocker) treatment reduces the incidence of reversion to AF in patients, possibly via an adaptive myocardial response.
Kane, K.A., Norrie, J., Rankin, A.C., Russell, J.A., Workman, A.J.   +4 more
core   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

PROPAFENONE FOR SINUS RHYTHM RECOVERY AND SUPPORT IN PATIENTS WITH PERSISTENT FORM OF AURICULAR FIBLILLATION. “PROMETHEUS” – OPENED MULTICENTER STUDY IN RUSSIAN FEDERATION

Рациональная фармакотерапия в кардиологии, 2016
Aim. To study efficiency and safety of propafenone internally used for recovery and support of sinus rhythm in patients with the persistent form of auricular fibrillation (AF). Material and methods. 503 patients with the persistent form of AF, aged 31-68
I. G. Fomina, A. I. Tarzimanova, A. V. Vetluzsky   +2 more
doaj   +2 more sources

Atypical Pre-excitation Pattern in Asymptomatic Wolff-Parkinson-White—A Hallmark for High Risk?

Romanian Journal of Cardiology
Delta wave morphology during sinus rhythm on 12 lead ECG usually allows for a relatively precise prediction of the anatomic location of an accessory pathway (AP) provided that the rhythm is fully pre-excited.
Burcin Alexandru-Paul, Ene Elena, Vătăşescu Radu-Gabriel   +2 more
doaj   +1 more source

A phenomap of TTR amyloidosis to aid diagnostic screening

ESC Heart Failure, Volume 12, Issue 2, Page 1113-1118, April 2025.
Abstract Cardiac amyloidosis due to transthyretin (ATTR) remains an underdiagnosed cause of cardiomyopathy. As awareness of the disease grows and referrals for ATTR increase, clinicians are likely to encounter more atypical forms of the condition in clinical practice.
Alexios S. Antonopoulos, Theodoros Tsampras, George Lazaros, Konstantinos Tsioufis, Charalambos Vlachopoulos   +4 more
wiley   +1 more source

Propafenone in restoring sinus rhythm among patients with persistent atrial fibrillation. PROMETEY – an open, multicenter, pilot study performed in the Russian Federation

Кардиоваскулярная терапия и профилактика, 2005
Aim. To study efficacy and safety of propafenone (loading single dose of 600 mg per os) in treating atrial fibrillation (AF) paroxysms. Material and methods. The study included 233 patients with persistent AF, aged 31-62 (mean age 57.6 ± 2.8 years), from
I. G. Fomina, A. I. Tarzimanova, A. V. Vetluzhsky, A. A. Abramova   +3 more
doaj  

Non-valvular atrial fibrillation and stroke : implications for management [PDF]

, 1995
Nonvalvular Atrial Fibrillation is more prevalent with increasing age. It is associated with a six-fold excess risk of stroke; and a cumulative lifetime stroke risk of 35%. 15% of ischaemic strokes are directly attributable to it.
Tilney, Myra Kay
core  

Left atrial function in uraemic patients: Four‐dimensional automatic left atrial quantitative technology study

ESC Heart Failure, Volume 12, Issue 2, Page 1316-1325, April 2025.
Abstract Objective This study aimed to evaluate the utility of left atrial volume and function in uraemic patients using four‐dimensional automatic left atrial quantification (4D auto LAQ) technology. Methods Thirty‐four undialysed uraemic patients (U‐ND group), 60 dialysed uraemic patients (U‐D group), and 32 healthy volunteers (N group) were enrolled
Bing Li, Meihua Chen, Xuning Huang
wiley   +1 more source